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Introduction 
 
Chronic liver diseases are progressive and associated with increasing functional 
impairment as a consequence of organ fibrosis. Whilst much effort has been 
directed at therapies that address underlying causes of disease such as hepatitis 
viruses or metabolic impairment in non-alcoholic fatty liver disease (NAFLD), 
effective treatments to prevent or reverse fibrogenesis have proven elusive and 
many patients die from the systemic complications of their cirrhosis despite 
successful management of the initiating disease. Persistent injury to the liver 
parenchyma drives hepatic fibrosis as part of a dysregulated repair response.  This is 
characterized by expansion of activated myofibroblasts which perpetuate the 
inflammation and increase production of extracellular matrix components such as 
collagen. Whilst many of the myofibroblasts arise as a consequence of activation of 
hepatic stellate cells, migration of cells from other sources such as the portal 
fibroblasts, bone marrow, and mesenchymal transformation of epithelial and 
endothelial cells all contribute to the myofibroblast pool1. Thus there is much 
interest in identifying factors that govern the activation of myofibroblasts or matrix 
remodeling that could be targeted in a therapeutic context2. The Transforming 
Growth Factor Beta (TGFβ) superfamily, consists of multiple individual protein 
isoforms and plays a key role in many fibrotic diseases. Dysregulated TGFβ signaling 
underpins virtually all fibrotic diseases, but the specific mechanisms and intracellular 
responses are context dependent. Here we consider a newly described contribution 
of TGFβ signaling in hepatic endothelial cells to consider whether this has potential 
as a therapy for fibrotic liver disease. 
 
The multiple and complex roles of TGFβ  
TGFβ is a pleiotropic cytokine with diverse roles in embryonic development, cell 
proliferation and differentiation, angiogenesis and wound healing responses. There 
are three protein isoforms TGFβ 1 to 3, which are similar structurally but vary in site 
of origin. These TGFβ isoforms play different roles in the scarring response, with 
TGFβ1 and β2 exerting pro-scarring effects and TGFβ3 favouring resolution. The 
TGFβ is initially secreted as a precursor form which undergoes conformational 
changes and proteolytic cleavage to generate a mature, active form and a latency 
associated peptide (LAP). There are various activators of TGFβ which include 
proteases that degrade LAP and molecules that non proteolytically disrupt the latent 
complex, including retinoids, MMPs and integrins3, 4. Activated TGFβ then binds to a 
receptor (TGFBR1 or 2) to initiate cellular responses. The downstream signaling 
initiated by TGFβ is complex and typically canonical (acting via Smad proteins) or 
non-canonical (Smad independent) leading to alterations in gene expression and 
function responses in target cells (reviewed in5). In the classical situation, activation 
of TGFBR2 phosphorylates TGFBR1 and Smad 2 and 3, these then interact with Smad 
4, which can cross the nuclear membrane and modify target gene expression. 
Importantly co activators and repressors of this pathway such as Smad7 can regulate 
TGFβ responses in a cell and context specific manner. 
 
Recently we collaborated with Anna Randi’s group at Imperial College and have 
reported6 that hepatic endothelial cell populations can contribute to the initiation of 
fibrosis by undergoing endothelial to mesenchymal transition (EndoMT).  Here 
endothelial cells lose the expression of characteristic cell surface markers and adopt 
a more mesenchymal phenotype in a process driven by TGFβ signaling. This process 
has been shown to contribute to fibrogenesis in atherosclerosis7 where it is linked to 
disease severity, vascular rejection of organ transplants and fibrotic lung and heart8 
disease. The endothelial transcription factor ERG is a key regulator in this process, 
controlling the balance between profibrotic and homeostatic TGFβ signaling.  The 
loss of ERG expression in response to proinflammatory signals in murine models of 
fibrosis and in a variety of human liver diseases including alcohol and fatty liver 
disease and cholangiopathies such as primary biliary cirrhosis (PBC), led to a smad3-
dependent loss in endothelial ERG expression and induction of mesenchymal 
markers such as smooth muscle actin. This was associated with early periportal 
collagen deposition and could be reversed by using TNFα blockade to restore ERG 
expression and reduce smad3 activity, although there were disease-specific 
differences in the magnitude of the effect. This suggests that therapeutic 
interference with smad signaling or blockade of TNFα may serve to modify fibrosis in 
specific subgroups of patients, for example those with fibrosis arising from 
cholangiopathies, and also that components of the non-canonical TGFβ signaling 
pathway may represent useful prognostic indicators in patients with liver disease.  
Interestingly reports suggest that some patients with autoimmune hepatitis that is 
resistant to standard therapies show excellent responses to anti-TNFα therapy9 
supporting the potential of targeting TNF in hepatic fibrosis. 
 
 
Are endothelial cells a good target for anti-fibrotic therapy? 
The change in endothelial phenotype termed EndoMT is associated with an 
increasing number of pathological conditions including portal hypertension, diabetic 
vasculopathies and atherosclerosis. The endothelium becomes mesenchymal in 
nature with increased secretory, migratory and proliferative capabilities, and TGFβ 
has been implicated in driving the response in many situations. In atherosclerosis7 
TGFβ upregulation and signaling through Smad3 drives increased extracellular matrix 
deposition and smooth muscle actin expression in proportion to disease severity. 
This suggests that targeting endothelial signaling could control atheroma lesion 
development. This concept also holds true in diabetic nephropathy where EndoMT 
driven by TGFβ signaling activates endothelial Smad3 and contributes to local 
collagen deposition. Here therapeutic potential is supported by the ability of a 
Smad3 activation inhibitor SIS3 to reduce both EndoMT and renal fibrosis in a 
diabetic model10. However it important to note that TGFβ has varied effects in 
endothelial cells that depend on the context and timing of signaling. Thus signaling 
associated with Smad1/5 is vital for proliferation in angiogenesis whereas activation 
of Smad2/3 inhibits both proliferation and migration. Similarly, populations of 
endothelial cells respond differently to Smad activation in a spatiotemporal manner 
that is in part dependent on the hemodynamic shear stress they are exposed too.  
Previous studies have associated changes in liver sinusoidal endothelial cell function 
(LSEC) with the development of fibrosis in end stage liver disease. Hepatic sinusoidal 
endothelial cells change their phenotype in chronic disease with the loss of 
characteristic surface receptors and fenestrations and the development of a more 
complex basement membrane in a process known as capillarization, analogous to 
EndoMT. This change precedes the development of fibrosis in a variety of liver 
diseases12 and importantly maintenance of mature, differentiated LSEC function 
prevents stellate cell activation. The finding that 6 endothelial ERG expression is 
linked to TGF signalling and periportal fibrosis adds credence to the concept of 
vascular targeting as a tool to modify fibrogenesis in the liver.  However, an 
important caveat relates to the possibility that different subpopulations of hepatic 
endothelial cells (eg portal vs sinusoidal or lymphatic) may respond or contribute 
differently in the context of specific liver diseases. 
 
Is targeting TGFβ signaling specifically a good strategy? 
An endothelial cell contribution to fibrogenesis has been reported in situations such 
as atheroma and nephropathy where the extent or proportion of fibrosis is relatively 
modest compared to that seen in hepatic cirrhosis. In the context of liver fibrosis, 
the proportion of scar tissue derived from dedifferentiated endothelial cells is likely 
to be small compared to that from the stellate-derived myofibroblasts. However, 
because reciprocal signaling between endothelial cells and hepatic stellate cells 
maintains both in a mature quiescent state, targeting the endothelium may also 
indirectly inhibit myofibroblast activation. In addition, although reducing the 
generation of extracellular matrix is of potential therapeutic value, reversal of 
cirrhosis requires extensive remodeling of established fibrotic tissue in an 
environment where the cytokine and growth factor milieu favours matrix 
crosslinking and stabilization rather than retraction resulting in scar tissue resistant 
to fibrolysis. It is likely that anti-fibrotic therapies will need to address the multi-
factorial aspect of fibrosis including reducing inflammation, preventing further 
deposition of scar, enhancing breakdown of pre-existing scar as well as promoting 
regeneration of normal liver architecture.  Alteration in endothelial TGFβ signaling 
alone is unlikely to accomplish this. Furthermore, there is a requirement to 
regenerate the damaged liver, and inhibition of TGFβ leads to morphological 
abnormalities, lack of endothelialization and stromal paucity in other tissues13. TGFβ 
-deficient mice die in utero due to a lack of normal vessel development and impaired 
angiogenesis is a feature of endothelial cells lacking the TGFβ receptor endoglin14. 
Furthermore endothelial TGFβ is central to the local control of VEGF production and 
hepatocyte regeneration 15. Thus targeting endothelial TGFβ signaling could have 
unwanted effects on angiogenesis and hepatic regeneration.  Endothelial cells can 
also present TGFβ to activate and maintain local regulatory T cells that are vital for 
control of immune responses and the prevention of autoimmunity16. Thus blockade 
of TGF responses could have detrimental effects on local immune regulation and 
thereby exacerbate chronic inflammation. 
 
In conclusion, there may be specific clinical circumstances where targeting EndoMT 
or angiogenic responses by modifying endothelial TGFβ signaling may be of benefit. 
One possibility could be to target angiogenesis in hepatic tumours, as it is clear that 
TGFβ1 is particularly relevant in this context and as most primary liver tumours arise 
in the context of cirrhosis, effects on fibrosis could also be investigated.   However, 
there is a need to better understand the complex effects of TGFβ and to develop 
methods specifically directed at the vasculature to minimize off target effects. 
Therapies can be directed specifically to hepatic endothelium by targeting receptors 
such as aminopeptidase P, and PV-1 which are restricted to endothelium with 
caveoli, or by targeting the range of scavenger receptors expressed on sinusoidal but 
not vascular endothelium.  In the context of liver fibrosis understanding the precise 
contribution of endothelial TGFβ contribution to the development of fibrogenesis is 
critical to determine whether therapeutic strategies are likely to be effective and if 
so when, and with what other treatments they should be combined. 
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